INTRODUCTION

Upon restoring blood supply after ischaemia, the liver is vulnerable to further injury, which aggravates the injury caused by ischaemia, termed ischaemia-reperfusion (I/R) injury. Hepatic I/R injury commonly occurs during surgical procedures such as hepatectomy and liver transplantation, leading to the graft dysfunction after transplantation. Multiple factors contribute to hepatic I/R injury, including mitochondrial damage, oxidative stress, intracellular Ca$^{2+}$ overload, activation of apoptotic kinases, cytokines and chemokines generated by kupffer cells and neutrophils. Some strategies have been developed to alleviate hepatic I/R injury, such as ischaemic preconditioning and postconditioning, and mechanical perfusion; however, these methods are associated with high cost and difficult clinical operation, despite their efficacy in reducing hepatic I/R injury. Therefore, developing potential pharmacological therapies are

Abstract

Hepatic ischaemia-reperfusion (I/R) injury constitutes a tough difficulty in liver surgery. Dexmedetomidine (Dex) plays a protective role in I/R injury. This study investigated protective mechanism of Dex in hepatic I/R injury. The human hepatocyte line L02 received hypoxia/reoxygenation (H/R) treatment to stimulate cell model of hepatic I/R. The levels of pyroptosis proteins and inflammatory factors were detected. Functional rescue experiments were performed to confirm the effects of miR-494 and JUND on hepatic I/R injury. The levels of JUND, PI3K/p-PI3K, AKT/p-AKT, Nrf2, and NLRP3 activation were detected. The rat model of hepatic I/R injury was established to confirm the effect of Dex in vivo. Dex reduced pyroptosis and inflammation in H/R cells. Dex increased miR-494 expression, and miR-494 targeted JUND. miR-494 inhibition or JUND upregulation reversed the protective effect of Dex. Dex repressed NLRP3 inflammasome by activating the PI3K/AKT/Nrf2 pathway. In vivo experiments confirmed the protective effect of Dex on hepatic I/R injury. Overall, Dex repressed NLRP3 inflammasome and alleviated hepatic I/R injury via the miR-494/JUND/PI3K/AKT/Nrf2 axis.

KEYWORDS

Dexmedetomidine, hepatic ischaemia-reperfusion injury, hypoxia/reoxygenation cell model, JUND, miR-494, NLRP3, PI3K/AKT/Nrf2 pathway, pyroptosis
critical for improving the prognosis of hepatic I/R injury, especially for those patients receiving surgery with prolonged ischaemia time or marginal liver transplantation.

The restoration of blood flow triggers tissue inflammation and ischaemic injury by activating multiprotein complex named inflammasome. Inflammasome is implicated in the pathogenesis of hepatic I/R injury, which is accepted as a crucial contributor to hepatocyte death initiated by inflammasomes. After inflammasome activation, the affected tissues undergo apoptosis and another inflammation-associated cell death, namely pyroptosis. Pyroptosis is a form of lytic programmed cell death initiated by inflammasomes. Pyroptosis is viewed as a universal and natural immune mechanism in vertebrates, which causes inflammation in bacterial infection and various non-infectious diseases including types of hepatic injury. Although there lacks direct evidence of the presence of pyroptosis in hepatic I/R injury, the inflammasome activation in hepatic I/R injury has been elucidated, indicating the involvement of pyroptosis in hepatic I/R injury.

Intriguingly, a previous study has unveiled that inhibition of pyroptosis ameliorates hepatic I/R injury and represses inflammatory reaction. Activation of some critical survival pathways or inhibition of apoptotic/ pyroptotic pathways using drugs or small molecules contributes to alleviating hepatic I/R injury before or during liver surgery or transplantation.

Dexmedetomidine (Dex), a highly selective α₂-adrenergic agonist, bears the potent properties of sedation and analgesia, which is extensively applied in critically ill and anaesthetic patients in clinical. Accumulating evidences have elucidated that Dex protects lung, cerebrum and liver against I/R injury by suppressing pro-inflammatory signalling and reducing cell death. For example, Dex exerts protective effect on hepatic I/R injury by repressing inflammatory response and oxidative stress in mice. Also, the differentially expressed microRNAs (miRNAs) are verified to participate in the mechanisms of Dex action. miRNA has been accepted as a novel target for treating hepatic I/R injury. miR-494 represses hypoxia/reoxygenation (H/R)-induced cardiomyocyte apoptosis. miR-494 attenuates hepatic I/R injury in a rat model. Overexpression of miR-494 upregulated HIF-1α expression under hypoxia and exerts protective effects against hypoxia-induced apoptosis, which suggests that miR-494 functions as a therapeutic target for hepatic I/R injury. Still, whether Dex can protect liver from I/R injury by targeting miR-494 remains unknown. This study investigated the specific protective mechanism of Dex in hepatic I/R injury, which shall confer novel insights into the management of hepatic I/R injury.

2 | MATERIALS AND METHODS

2.1 | Ethics statement

All the animal experiments were implemented on the guide for the care and use of laboratory animals and on minimized animal number and the least pains.

2.2 | Cell model of H/R

The 293T and human hepatocyte line L02 (Shanghai Institute of Cellular Biology of Chinese Academy of Sciences, Shanghai, China) were identified by STR profiling, and there was no mycoplasma contamination. Cells were cultured in high glucose-Dulbecco’s modified Eagle’s medium (4.5 g/L) containing 10% PAN at 37°C with 5% CO₂. Cells were firstly cultured in HERAcell 150i incubator (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C for 24 h under hypoxia condition (94% N₂, 5% CO₂ and 1% O₂) and then transferred to typical incubator (21% O₂ and 5% CO₂) for 4 h for reoxygenation. The cell model induced by H/R was established. After modelling, cells were treated with Dex (20 μM) for 24 h.

2.3 | Cell transfection and grouping

H/R model cells or 293T cells were transfected with mimic NC, miR-494 mimic, inhibitor NC, miR-494 inhibitor, pcDNA3.1-NC or pcDNA3.1-JUND (GeneChem, Shanghai, China) (miRNA-inhibitor 50 nM, miRNA-mimic 30 nM and pcDNA3.1 10 nM) using LipoFectamine 2000 (11668-019, Invitrogen, Carlsbad, CA, USA). The subsequent experiments were performed after 48 h. Cells were assigned into blank group (untreated L02 cells), H/R group (H/R-treated L02 cells), H/R + DEX group (cells were treated with 20 μM Dex for 3 h and then received H/R treatment), H/R + DEX + inhibitor NC group (cells were treated with 20 μM Dex for 3 h and received H/R and then transfected with inhibitor NC), H/R + DEX + inhibitor group (cells were treated with 20 μM Dex for 3 h and received H/R and then transfected with miR-494 inhibitor), H/R + DEX + pcDNA3.1-NC group (cells were treated with 20 μM Dex for 3 h and received H/R and then transfected with pcDNA3.1-NC) and H/R + DEX + pcDNA3.1-JUND group (cells were treated with 20 μM Dex for 3 h and received H/R and then transfected with pcDNA3.1-JUND).

2.4 | Enzyme-linked immunosorbent assay (ELISA)

The levels of alanine aminotransferase (ALT) (ab234579, Abcam Inc., Cambridge, MA, USA), aspartate aminotransferase (AST) (ab263883, Abcam), IL-6 (ab178013, Abcam), TNF-α (ab181421, Abcam), IL-1β (ab217608, Abcam) and IL-18 (ab215539, Abcam) was detected using ELISA kits. Briefly, the sample to be tested (containing antibody) was bound to antigen, and then, the labelled enzyme was bound to the complex to form antigen-antibody-labelled enzyme complex. The enzyme substrate was added to produce coloured product, and its optical density value was determined by spectrophotometer.

2.5 | Western blotting

Cells or tissues were treated with RIPALysis buffer to extract the total protein, and the protein concentration was detected using
the bicinchoninic acid kit (Pierce, Waltham, MA, USA). The protein sample was separated by 12% SDS-PAGE and transferred onto cellulose nitrate membranes (Bio-Rad Laboratories Inc., Hercules, CA, USA). The membranes were blocked with phosphate-buffered saline containing 5% skim milk for 2 h and incubated with the primary antibodies at 4°C overnight and then with the secondary antibodies for 2 h. The protein band was developed using enhanced chemiluminescence kit (Thermo Fisher Scientific) and quantified using ImageJ software. The primary antibodies were as follows: anti-ASC (1:1000, ab151700, Abcam), anti-Gasdermin-D (GSDMD)-N (1:1000, ab152503, Abcam), anti-caspase-1 (1:1000, ab207802, Abcam), anti-PI3K (1:2000, sc-166365, Santa Cruz Biotechnology, Inc, Santa Cruz, CA, USA), anti-p-PI3K (1:5000, ab182651, Abcam), anti-AKT (1:1000, sc-5298, Santa Cruz Biotechnology), anti-p-AKT (1:1000, sc-293125, Santa Cruz Biotechnology), anti-ASC (1:1000, ab89443, ab92946, Abcam), anti-NLRP3 (1:1000, ab214185, Abcam) and anti-GAPDH (1:1000, sc-47724, Santa Cruz Biotechnology). The secondary antibodies were anti-mouse IgG (1:2000, sc-516102, Santa Cruz Biotechnology) and anti-rabbit IgG (1:2000, sc-2357, Santa Cruz Biotechnology).

### 2.6 | Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNA was extracted from cells or tissues using TRIzol reagent (Takara, Tokyo, Japan), and 500 ng total RNA was reverse transcribed into cDNA using PrimeScript RT Reagent kit (Takara). CFX 96 qPCR system (Bio-Rad) and SYBR RT-PCR kit (Takara) were used for RT-qPCR. The relative expression of miR-494 and JUND was calculated by \(2^{-\Delta\Delta CT}\) method, with GAPDH and U6 as the internal reference. Each sample was repeated 3 times independently. Primer sequences are shown in Table 1.

### 2.7 | Animal model

Sprague Dawley (SD) rats of specific pathogen-free (SPF) grade (weighing 190–210 g and aged 9–10 weeks) were provided by Shantou University Medical College [SCXK (Guangdong) 2017-0017]. The rats were reared in SPF animal room at 60% humidity and 22–24°C. Food and water were provided ad libitum. The rats were maintained in a 12 h light/dark cycle.

antagomiR-494 and antagomiR-NC were purchased from GenScript (Nanjing, Jiangsu, China). The rats were administered via tail vein 3 days before modelling (consecutive 3 days; 40 μg/g).

The rats were anaesthetized by intraperitoneal injection of 1% pentobarbital (50 mg/kg) and fixed on the heating pad in supine position. The incision was made along the midline of the upper abdomen. The hepatic pedicle was clamped with a non-invasive microvascular clamp, and hepatic I/R was induced 60 min later. Dex was administered intravenously at the beginning of the operation at a loading dose of 3 μg/kg and then at a dose of 3 μg/kg/min for the next 2 h. The rats in the sham group received all operations except clamping the hepatic pedicle. After abdominal suture, the rats were allowed to recover with free access to food and water. After 24 h of reperfusion, rats were euthanized by intraperitoneal injection of 1% pentobarbital (800 mg/kg). The blood was extracted from left ventricle by a syringe, centrifuged at 2000 g and 4°C for 15 min and stored at −80°C. The rat liver tissues were collected and fixed in 4% paraformaldehyde. The rats were assigned into sham group (rats received all operations except clamping the hepatic pedicle), I/R group (rats received I/R treatment and intravenous injection of Dex), I/R + DEX group (rats received I/R treatment and intravenous injection of Dex) and I/R + DEX + antagomiR-494 group (after antagomiR-494 transfection, rats received I/R treatment and intravenous injection of Dex). Each group had 12 rats, among which 6 rats were used for tissue section staining and 6 rats were used for protein or RNA extraction and detection.

### 2.8 | Haematoxylin and eosin (HE) staining

The liver tissues fixed in 4% paraformaldehyde for 24 h were embedded in paraffin, sliced continuously with the thickness of 5 μm, baked at 58°C for 18 h and dewaxed with xylene and hydrated. The sections were incubated in haematoxylin solution for 15 min and stained with eosin solution for 15 s. The sections were dehydrated, cleared and sealed, followed by observation under optical microscope.
2.9 | Suzuki score

Suzuki score was used to evaluate liver tissue injury in rats, and the Suzuki score criteria are shown in Table 2 below.

2.10 | Immunohistochemical staining

The liver tissue sections were treated with 0.01 mol/L citric acid buffer (95°C 5 min × 2 times) for antigen retrieval and incubated with 3% H2O2 at room temperature for 15 min and with the primary antibody anti-NLRP3 (1:200, ab214185, Abcam) at 4°C overnight. Afterwards, the sections were cultured with the secondary antibody anti-rabbit IgG (1:2000, ab150077, Abcam) for 30 min, stained with 3-diaminobenzidine (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany), washed with running water and then counterstained with haematoxylin.

2.11 | Statistical analysis

Data were analysed and introduced using SPSS 21.0 (IBM Corp., Armonk, NY, USA). Data are expressed as mean ± standard deviation. Kolmogorov-Smirnov test was used to test the normal distribution. The t test was adopted for comparison between two groups. One-way analysis of variance (ANOVA) was employed for the comparisons among multiple groups, following Tukey’s multiple comparisons test. The p value was obtained from a two-tailed test and the p < 0.05 meant the statistically significance.

| Score | Congestion (%) | Vacuolization (%) | Necrosis (%) |
|-------|----------------|-------------------|-------------|
| 0     | None           | None              | None        |
| 1     | Minimal (10)   | Minimal (10)      | Single cell necrosis |
| 2     | Mild (11–30)   | Mild (11–30)      | Mild (<30)  |
| 3     | Moderate (31–60)| Moderate (31–60)  | Moderate (>60) |
| 4     | Severe (>60)   | Severe (>60)      | Severe (>60) |

**TABLE 2** Suzuki’s criteria of hepatic I/R injury

![Figure 1](image1.png)

**FIGURE 1** Dex exerted protective effects by suppressing pyroptosis. The H/R cell model was treated with Dex. A, The pyroptotic proteins ASC, GSDMD-N and caspase-1 in H/R cells were detected using Western blotting. B, The contents of IL-1β and IL-18 were detected using ELISA. The cell experiment was repeated 3 times. Data were presented as mean ± standard deviation and analysed using one-way ANOVA, followed by Tukey’s multiple comparison test. *** p < 0.001
3. RESULTS

3.1 | Dex exerted protective effects on hepatic I/R injury by suppressing pyroptosis

To observe the effect of Dex on cell model, we simulated hepatic I/R injury in human hepatocyte line L02 through H/R treatment. Pyroptosis, also known as inflammatory necrosis, is characterized by cell swelling until cell membrane rupture, leading to the release of cellular contents and activation of strong inflammatory response.25 We speculated that Dex played a protective role by suppressing pyroptosis. The protein levels of ASC, GSDMD-N and caspase-1, and the contents of IL-1β and IL-18 were detected using Western blotting and ELISA (Figure 1A,B). The results revealed that the levels of ASC, GSDMD-N, IL-1β and IL-18 in the H/R group were notably higher than those in the blank group, while Dex treatment decreased the levels of ASC, GSDMD-N, IL-1β and IL-18 (all \( p < 0.001 \)). Briefly, Dex protected the cell model of I/R injury by suppressing pyroptosis.

3.2 | Dex protected H/R cells through miR-494

miRNA plays a vital role in hepatic I/R injury and may become a novel tool to diagnose and monitor hepatic I/R injury.26 miR-494 can play a protective role in liver I/R injury.25 Therefore, we speculated that Dex protected H/R-treated cells through miR-494. miR-494 expression of L02 cells in the blank group, H/R group and
H/R + DEX group (Figure 2A) was detected using RT-qPCR. The results demonstrated that H/R treatment downregulated miR-494 expression of L02 cells ($p < 0.001$), while Dex inhibited the downregulation of miR-494 to a certain extent ($p < 0.001$). Subsequently, we transfected miR-494 inhibitor into H/R cells to further verify the role of miR-494 (Figure 2A). The levels of ASC, GSDMD-N and caspase-1, and the contents of IL-1$\beta$ and IL-18 were detected (Figure 2B,C): miR-494 inhibitor reversed the protective effect of Dex on H/R cell pyroptosis and attenuated the inhibition of Dex on inflammatory factors. Briefly, Dex attenuated H/R cell pyroptosis by upregulating miR-494.

### 3.3 miR-494 targeted JUND

To investigate the potential mechanism of miR-494 in H/R cells, we predicted the downstream targets of miR-494 through Starbase (http://starbase.sysu.edu.cn/), TargetScan (http://www.targetscan.org/vert_72/) and Jefferson (https://cm.jefferson.edu/rna22/Precomputed/). After taking the intersection, we focused on JUND (Figure 3A), because accumulating evidences have unveiled the role of JUND in liver injury.27,28 Next, the dual-luciferase reporter assay in HEK293T cells verified the binding relationship between miR-494 and JUND (Figure 3B). Subsequently, the relative expression of JUND in the above experimental groups was detected using RT-qPCR (Figure 3C), and the results exhibited that miR-494 suppressed JUND expression. Briefly, miR-494 targeted JUND.

### 3.4 Upregulation of JUND reversed the protective effect of Dex on H/R cells

To verify the regulatory mechanism of the above targeting relationship in Dex, we transfected pcDNA3.1-JUND into cells. RT-qPCR confirmed the transfection efficiency (Figure 4A). The release of pyroptosis proteins and inflammatory factors were detected using Western blotting and ELISA (Figure 4B,C): overexpression of JUND partially reversed the effect of Dex on H/R cells. It was suggested that upregulation of JUND reversed the protective effect of Dex on H/R cells.

### 3.5 Dex repressed NLRP3 inflammasome by activating the PI3K/AKT/Nrf2 pathway

PI3K/AKT/Nrf2 pathway is implicated in the protection of liver injury.29,30 Therefore, we detected the levels of PI3K/p-PI3K,
AKT/p-AKT and Nrf2 in each group (Figure 5A). The results revealed that H/R treatment inhibited the phosphorylation of PI3K and AKT and the expression of Nrf2, while Dex reversed these trends to some extent (p < 0.001), thus promoting the activation of the PI3K/AKT/Nrf2 pathway. Nrf2 activation restrains the NLRP3 inflammasome activation, which was also observed by Western blotting (Figure 6A). Combined with the changes of inflammatory factors (ASC, GSDMD-N, caspase-1, IL-1β and IL-18) and the expressions of miR-494 and JUND, it was indicated that Dex repressed the activation of the PI3K/AKT/Nr12 pathway via miR-494/JUND, thus suppressing NLRP3 inflammasome.

3.6 | Dex protected hepatic I/R injury in vivo

To verify the above cell experiment results, we established the rat model of hepatic I/R injury. miR-494 mRNA expression and JUND protein level in the rats were detected (Figure 6A). The levels of ALT and AST in the serum of rats in the I/R group were higher than those in the sham group, while Dex reduced the levels of ALT and AST (Figure 6B) (p < 0.001). The rat liver sections were observed by HE staining (Figure 6C): Dex treatment notably decreased Suzuki score of hepatic injury (p < 0.001); NLRP3 expression was detected by immunohistochemical staining (Figure 6D): NLRP3 was significantly enhanced in the I/R group, while Dex decreased the positive expression of NLRP3. Inhibition of miR-494 reversed the protective effect of Dex (p < 0.001). JUND expression in vivo was detected using RT-qPCR (Figure 6A). The phosphorylation of PI3K/AKT/Nr12 pathway-related proteins and the NLRP3 protein level were detected using Western blotting (Figure 6E). The results were consistent with the above cell experiment results (p < 0.001). Taken together, Dex exerted protective effect on hepatic I/R injury in rats.
DISCUSSION

The liver is highly dependent on oxygen supply and vulnerable to hypoxia; and the adverse consequences of hepatic I/R injury remain a tough issue in clinical practice.33 Dex is an anaesthetic adjuvant that can reduce inflammatory reaction during the perioperative period, suggesting that it may become a novel therapeutic approach to alleviate I/R injury.34 The pathogenesis of hepatic I/R injury includes the occurrence of oxidative stress and the release of pro-inflammatory factors, and Ma XG, et al. found that Dex reduced H/R-induced elevation of ROS and MDA levels.35 Meanwhile, Zhou H, et al. found that Dex pretreatment can promote the activation of macrophage M2 and inhibit the activation of hepatic inflammatory innate immunity in a PPARγ/STAT3 dependent manner.36 In this study, we found that Dex pretreatment can promote the activation of macrophage M2 and inhibit the activation of hepatic inflammatory innate immunity in a PPARγ/STAT3 dependent manner.36 In this study, we found that Dex regulates the activation of NLRP3 inflammasomes by regulating miR-494/JUND, which further confirmed that Dex protects hepatic I/R by inhibiting inflammation in the liver.

Hepatic I/R induces inflammation and oxidative stress, resulting in the injury of liver and distant organs.37 Dex alleviates inflammatory response and shows protective effect in various animal models of I/R injury.13 The liver enzymes ALT and AST are commonly utilized to evaluate hepatic injury; and α-GST serves as a sensitive marker of hepatic I/R injury.38 Our results demonstrated that Dex treatment notably reduced the levels of α-GST, IL-6, TNF-α, ALT and AST in serum, suggesting that Dex exerted protective effects on hepatic I/R injury clinically. Dex mitigates hepatic I/R injury, and its protective mechanism may be concerned with reducing biochemical factors AST and ALT and inflammatory cytokines and enhancing Bcl-2, thereby attenuating inflammatory response and suppressing apoptosis in mice.18,24 Our study confirmed the protective role of Dex in hepatic I/R injury.

To observe the effect of Dex on cell model, we simulated hepatic I/R injury in human liver cell line LO2 through H/R treatment. Inflammasome activation has been recently described as a promising therapeutic target of hepatic I/R injury.39 Typical inflammasomes, including NLRP3, recruit caspase-1 under a series of microbial stimulation and endogenous risk signals, and then caspase-1 induces a form of lytic programmed cell death called pyroptosis.40 It is well established that inflammasome activation is responsible for pyroptosis.41 Pyroptosis is featured by the activation of caspase-1, which eventually results in the cleavage of GSDMD and the secretion of IL-1β and IL-18.37 GSDMD is a genetic substrate of inflammatory caspases, which is implicated in pyroptosis and IL-1β release.25 ASC represents a scaffold protein that is essential to recruit effector enzyme pro-caspase-1 into NLRP3 inflammasome.42 Accumulating evidences have unveiled the critical role of pyroptosis in the pathological process of hepatic I/R, and repression of pyroptosis contributes to alleviating hepatic I/R injury.25,43,44 Accordingly, we found that Dex treatment decreased the levels of ASC, GSDMD-N, IL-1β and IL-18, indicating that Dex protected the cell model of I/R injury by suppressing pyroptosis. Dex is demonstrated to suppress caspase-1 activation and reduce pyroptosis, thus protecting cells...
FIGURE 6  Dex protected hepatic I/R injury in vivo. The rat model of hepatic I/R was established. A, miR-494 and JUND expression was detected using RT-qPCR. B, The levels of ALT and AST in serum of rats were detected using ELISA. C, The rat liver sections were stained with HE staining. D, The rat liver sections were stained with immunohistochemical staining. E, The changes of JUND, p-AKT, AKT, Nrf2 and NLRP3 were detected using Western blotting. N = 6. Data were presented as mean ± standard deviation and analysed using one-way ANOVA, followed by Tukey's multiple comparison test, *** p < 0.001
from HMGB1-induced cell injury.45 Consistently, Dex ameliorates myocardial I/R injury in rats and represses H/R-induced pyroptosis in cardiomyocytes by reducing miR-29b.46 These results indicated that Dex protected the cell model of I/R injury by suppressing pyroptosis.

Then, we investigated the molecular mechanism of Dex protecting liver from I/R injury. Aberrant miRNA expression is implicated in the pathogenesis of I/R injury, because they modulate the cell participants and humoral factors related to I/R injury.26 miR-494 is differentially expressed in cerebral I/R injury in rats and shows protective effect on myocardial I/R injury.46 We speculated that Dex protected H/R cells through miR-494. As our results indicated, H/R treatment downregulated miR-494 expression, while Dex inhibited the downregulation of miR-494 to a certain extent. Additionally, miR-494 inhibitor reversed NLRP3 inflammasome and alleviating hepatic I/R injury. This study simply revealed that Dex inhibited inflammation through miR-494 and its target gene to protect liver from I/R injury, but the specific mechanism of Nrf2 in NLRP3 inflammasome failed to be deeply studied. Nrf2 activation is tightly related to its entry and exit from the nucleus, and the regulation mechanism of out- and inside nucleus of Nrf2 in NLRP3 remains to be studied. In the future, we will further study on the mechanism of Nrf2 in regulating NLRP3, which may provide novel insights into the clinical treatment of hepatic I/R injury.

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

AUTHOR CONTRIBUTIONS
Yan Wu: Conceptualization (equal); data curation (equal); methodology (equal); project administration (equal); writing–review and editing (equal). Gaolin Qiu: Conceptualization (equal); data curation (equal); writing–original draft (equal); writing–review and editing (equal). Hairong He: Formal analysis (equal); methodology (equal). Leilei Zhu: Methodology (equal); supervision (equal). Gao Cheng: Investigation (equal); writing–review and editing (equal). Yiqiao Wang: Formal analysis (equal); writing–original draft (equal). Yuanhai Li: Data curation (equal); formal analysis (equal). Weiwei Wu: Data curation (equal); formal analysis (equal); writing–original draft (equal); writing–review and editing (equal).

DATA AVAILABILITY STATEMENT
All the data generated or analysed during this study are included in this published article.

ORCID
Weiwei Wu https://orcid.org/0000-0002-9533-6417

REFERENCES
1. Saidi RF, Kenari SK. Liver ischemia/reperfusion injury: an overview. J Invest Surg. 2014;27:366-379.
2. Peralta C, Jimenez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. J Hepatol. 2013;59:1094-1106.
3. Cannistra M, Ruggiero M, Zullo A, et al. Hepatic ischemia reperfusion injury: a systematic review of literature and the role of current drugs and biomarkers. Int J Surg. 2016;33(Suppl 1):S57-70.
4. Yang W, Chen J, Meng Y, Chen Z, Yang J. Novel Targets for Treating Ischemia-Reperfusion Injury in the Liver. J Invest Surg. 2013;59:1094-1106.
5. Mohamadi Y, Mousavi M, Khanbabaei H, et al. The role of inflammasome complex in ischemia-reperfusion injury. J Cell Biochem. 2018;27:1-10.
6. Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387-400.
7. Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol. 2011;11:213-220.
8. Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42:245-254.
9. Li Z, Zhao F, Cao Y, et al. DHA attenuates hepatic ischemia reperfusion injury by inhibiting pyroptosis and activating PI3K/Akt pathway. Eur J Pharmacol. 2018;835:1-10.
10. Kim HY, Kim SJ, Lee SM. Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/reperfusion. FEBS J. 2015;282:259-270.

11. Li J, Zhao J, Xu M, et al. Blocking GSDMD processing in innate immune cells but not in hepatocytes protects hepatic ischemia-reperfusion injury. Cell Death Dis. 2020;11:244.

12. Li A, Yuen VM, Goulay-Dufay S, Kwok PC. Pharmacokinetics and pharmacodynamics of dexmedetomidine. Drug Dev Ind Pharm. 2016;42:1917-1927.

13. Cai Y, Xu H, Yan J, et al. Molecular targets and mechanism of action of dexmedetomidine in treatment of ischemia/reperfusion injury. Mol Med Rep. 2014;9:1542-1550.

14. Cheng J, Zhu P, Qin H, et al. Dexmedetomidine attenuates cerebral ischemia/reperfusion injury in neonatal rats by inhibiting TLR4 signaling. J Int Med Res. 2018;46:2925-2932.

15. Liang S, Wang Y, Liu Y. Dexmedetomidine alleviates lung ischemia-reperfusion injury in rats by activating PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 2019;23:370-377.

16. Sun Z, Zhao T, Lv S, et al. Dexmedetomidine attenuates spinal cord ischemia-reperfusion injury through both anti-inflammation and anti-apoptosis mechanisms in rabbits. J Transl Med. 2018;16:209.

17. Wang Yi, Wu S, Yu X, et al. Dexmedetomidine Protects Rat Liver against Ischemia-Reperfusion Injury Partly by the α2A-Adrenoceptor Subtype and the Mechanism Is Associated with the TLR4/NF-κB Pathway. International Journal of Molecular Sciences. 2016;17(7):995-1006. http://dx.doi.org/10.3390/ijms17079995

18. Chen Z, Ding T, Ma CG. Dexmedetomidine (DEX) protects against hepatic ischemia/reperfusion (I/R) injury by suppressing inflammation and oxidative stress in NLRCS deficient mice. Biochem Biophys Res Commun. 2017;493:1143-1150.

19. Yang X, Chen H, Chen Y, et al. Circulating miRNA expression profiling and target prediction in patients receiving dexmedetomidine. Cell Physiol Biochem. 2018;50:552-568.

20. Ning S, Li Z, Ji Z, et al. MicroRNA494 suppresses hypoxia/reoxygenationinduced cardiomyocyte apoptosis and autophagy via the PI3K/AKT/mTOR signaling pathway by targeting SIRT1. Mol Med Rep. 2020;22:5231-5242.

21. Su S, Luo D, Liu X, et al. miR-494 up-regulates the PI3K/Akt pathway via targeting PTEN and attenuates hepatic ischemia/reperfusion injury in a rat model. Bioscience Reports. 2017;37(5). http://dx.doi.org/10.1042/bsr20170798

22. Sun G, Zhou Y, Li H, et al. Over-expression of microRNA-494 up-regulates hypoxia-inducible factor-1 alpha expression via PI3K/Akt pathway and protects against hypoxia-induced apoptosis. J Biomed Sci. 2013;20:100.

23. Lv M, Zeng H, He Y, et al. Dexmedetomidine promotes liver regeneration in mice after 70% partial hepatectomy by suppressing NLRP3 inflammasome not TLR4/NF-kappaB. Int Immunopharmacol. 2018;54:46-51.

24. Lim H, Kim TY, Kim SY, et al. The protective effects of dexmedetomidine preconditioning on hepatic ischemia-reperfusion injury in rats. Transplant Proc. 2021;53:427-435.

25. Hua S, Ma M, Fei X, et al. Glycyrhizin attenuates hepatic ischemia-reperfusion injury by suppressing HMGB1-dependent GSDMD-mediated kuffer cells pyroptosis. Int Immunopharmacol. 2019;68:134-155.

26. Christou CD, Tsoufas G. The role of microRNA in hepatic ischemia/reperfusion injury. Microm. 2020;9:248-254.

27. Huang S, Ju W, Zhu Z, et al. Comprehensive and combined omics analysis reveals factors of ischemia-reperfusion injury in liver transplantation. Epigenomics. 2019;11:527-542.

28. Sun Y, Pan H, Shen S, et al. Alisma Shugan Decoction (ASD) alleviates hepatotoxicity and associated liver dysfunction by inhibiting oxidative stress and p65/Nrf2/JunD signaling dysregulation in vivo. Med Sci Monit. 2020;26:e921738.

29. Ma X, Zhang W, Jiang Y, et al. Paeoniflorin, a natural product with multiple targets in liver diseases-a mini review. Front Pharmacol. 2020;11:531.

30. Thangapandiyans S, Ramesh M, Hema T, et al. Sulforaphane potentially ameliorates arsenic induced hepatotoxicity in albino wistar rats: implication of PI3K/Akt/Nrf2 signaling pathway. Cell Physiol Biochem. 2019;52:1203-1222.

31. Ahmed SMU, Luo L, Namani A, et al. Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis. 2017;1863:585-597.

32. Suzuki S, Toledo-Pereyra LH. Interleukin 1 and tumor necrosis factor production as the initial stimuli of liver ischemia and reperfusion injury. J Surg Res. 1994;57:253-258.

33. Papadopoulos D, Siemps T, Theodorakou E, Tsoulfas G. Hepatic ischemia and reperfusion injury and trauma: current concepts. Arch Trauma Res. 2013;2:63-70.

34. Wang K, Wu M, Xu J, et al. Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis. Br J Anaesth. 2019;123:777-794.

35. Ma XG, Liu Y, Xue MX. [Dexmedetomidine alleviates hepatic ischemia-reperfusion injury by regulating MALAT1/miR-126-5p/HMG1 axis]. Sheng Li Xue Bao. 2021;73:253-262.

36. Zhou H, Sun J, Zhong W, et al. Dexmedetomidine preconditioning alleviated murine liver ischemia and reperfusion injury by promoting macrophage M2 activation via PPARgamma/STAT3 signaling. Int Immunopharmacol. 2020;82:106363.

37. Zhang L, Liu H, Jia L, et al. Exosomes mediate hippocampal and cortical neuronal injury induced by hepatic ischemia-reperfusion injury through activating pyroptosis in rats. Oxid Med Cell Longev. 2019;2019:3753485.

38. Zhang YU, Liu M, Yang YU, et al. Dexmedetomidine exerts a protective effect on ischemia-reperfusion injury after heptectomy: a prospective, randomized, controlled study. J Clin Anesth. 2020;61:109631.

39. Jimenez-Castro MB, Cornide-Petronio ME, Gracia-Sanco J, Peralta C. Inflammasome-mediated inflammation in liver ischemia-reperfusion injury. Cells. 2019;8:1131-1156.

40. Aachoui Y, Sagulenko V, Miao EA, Stacey KJ. Inflammasome-mediated pyroptotic and apoptotic cell death, and defense against infection. Curr Opin Microbiol. 2013;16:319-326.

41. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821-832.

42. Sutterwala FS, Haasen S, Cassel SL. Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci. 2014;1319:82-95.

43. El-Sisi AEE, Sokar SS, Shebil AM, et al. Octreotide and melatonin alleviate inflammasome-induced pyroptosis through inhibition of TLR4-NF-kappaB-NLRP3 pathway in hepatic ischemia/reperfusion injury. Toxicol Appl Pharmacol. 2021;410:115340.

44. Wang X, Liu Z, Shen L. [Sulforane preconditioning inhibits caspase-11-related noncanonical pyroptosis pathway to alleviate hepatic ischemia-reperfusion injury in mice]. Nan Fang Yi Ke Da Xue Xue Bao. 2020;40:670-675.

45. Ji X, Guo Y, Zhou G, et al. Dexmedetomidine protects against high mobility group box 1-induced cellular injury by inhibiting pyroptosis. Cell Biol Int. 2019;43:651-657.

46. Zhong Yi, Li Y-P, Yin Y-Q, et al. Dexmedetomidine inhibits pyroptosis by down-regulating miR-29b in myocardial ischemia reperfusion injury in rats. Int Immunopharmacol. 2020;86:107678.

47. Zhai F, Zhang X, Guan Y, et al. Expression profiles of microRNAs after focal cerebral ischemia/reperfusion injury in rats. Neural Regen Res. 2012;7:917-923.

48. Wang X, Zhang X, Ren X-P, et al. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation. 2010;122:1308-1318.

49. Diaz-Castro E, Reiner MF, Bonetti NR, et al. AP-1 (Activated Protein-1) transcription factor JunD regulates ischemia/
reperfusion brain damage via IL-1beta (Interleukin-1beta). Stroke. 2019;50:469-477.

50. Akhmedov A, Montecucco F, Costantino S, et al. Cardiomyocyte-specific JunD overexpression increases infarct size following ischemia/reperfusion cardiac injury by downregulating Sirt3. Thromb Haemost. 2020;120:168-180.

51. Li S, Yi Z, Deng M, et al. TSLP protects against liver I/R injury via activation of the PI3K/Akt pathway. JCI Insight. 2019;4(22):1-13.

52. Li Y, Tong L, Zhang J, Zhang Y, Zhang F. Galangin alleviates liver ischemia-reperfusion injury in a rat model by mediating the PI3K/AKT pathway. Cell Physiol Biochem. 2018;51:1354-1363.

53. Rabie MA, Zaki HF, Sayed HM. Telluric acid ameliorates hepatic ischemia reperfusion-induced injury in rats: involvement of TLR4, Nrf2, and PI3K/Akt signaling pathways. Biochem Pharmacol. 2019;168:404-411.

54. Ke B, Shen X-D, Zhang YU, et al. KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants. J Hepatol. 2013;59:1200-1207.

55. Zhang Q, Lai Y, Deng J, et al. Vagus nerve stimulation attenuates hepatic ischemia/reperfusion injury via the Nrf2/HO-1 pathway. Oxid Med Cell Longev. 2019;2019:9549506.

56. Kudoh K, Uchinami H, Yoshioka M, et al. Nrf2 activation protects the liver from ischemia/reperfusion injury in mice. Ann Surg. 2014;260:118-127.

57. Guo Z, Yu S, Chen X, et al. NLRP3 is involved in ischemia/reperfusion injury. CNS Neurol Disord Drug Targets. 2016;15:699-712.

58. Hennig P, Garstkiewicz M, Grossi S, et al. The crosstalk between Nrf2 and inflammasomes. Int J Mol Sci. 2018;19:562-580.

59. Zhu P, Duan L, Chen J, et al. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum Gene Ther. 2011;22:853-864.

---

**How to cite this article:** Wu Y, Qiu G, Zhang H, et al. Dexmedetomidine alleviates hepatic ischaemia-reperfusion injury via the PI3K/AKT/Nrf2-NLRP3 pathway. *J Cell Mol Med.* 2021;25:9983–9994. [https://doi.org/10.1111/jcmm.16871](https://doi.org/10.1111/jcmm.16871)